{"id":19792,"date":"2021-09-27T13:53:35","date_gmt":"2021-09-27T18:53:35","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/ecd-staging\/?post_type=study_trials&#038;p=19792"},"modified":"2021-09-27T13:54:50","modified_gmt":"2021-09-27T18:54:50","slug":"low-dose-selinexor-and-choline-salicylate-for-the-treatment-of-patients-with-residual-relapsed-or-refractory-non-hodgkin-lymphoma","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/es\/study_trials\/low-dose-selinexor-and-choline-salicylate-for-the-treatment-of-patients-with-residual-relapsed-or-refractory-non-hodgkin-lymphoma\/","title":{"rendered":"Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma"},"content":{"rendered":"<p><strong>Objetivo del estudio:<\/strong> To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed\/refractory diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). (Primary)<\/p>\n<p><strong>Investigador principal:<\/strong> &nbsp;Jonas Paludo, M.D., Mayo Clinic in Rochester, Minnesota, United States<\/p>\n<p><strong>Datos de contacto:<\/strong> Clinical Trials Referral Office &nbsp; Phone: +1-855-776-0015&nbsp; &nbsp;Email: <a href=\"mailto:mayocliniccancerstudies%40mayo.edu?subject=NCT04640779,%20LS1981,%20Low-Dose%20Selinexor%20and%20Choline%20Salicylate%20for%20the%20Treatment%20of%20Patients%20With%20Residual,%20Relapsed%20or%20Refractory%20Non-Hodgkin%20Lymphoma\">mayocliniccancerstudies@mayo.edu<\/a>&nbsp;&nbsp;<\/p>\n<p><strong>Participaci\u00f3n solicitada del paciente:<\/strong> 18 Years and older&nbsp;<\/p>\n<p><strong>Identificador de ClinicalTrials.gov:<\/strong> NCT04640779<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed\/refractory diffuse large B cell lymphoma [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32,129],"class_list":["post-19792","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial","study_trials_cat-interventional"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials\/19792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/media?parent=19792"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials_cat?post=19792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}